Treatment options for managing atherogenic dyslipidemia and fatty liver disease

Manfredi Rizzo, Giuseppe Montalto, Khalid Al-Rasadi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries with up to 30% of the population affected. Since NAFLD is associated with an increased risk of cardiovascular (CV) disease, these patients should be stratified for CV risk factors, including atherogenic dyslipidemia, and managed accordingly. Lifestyle modifications represent an effective treatment for NAFLD, since most patients are overweight or obese. Also, promising, but not conclusive, results are available for current pharmacologic treatment. Drugs potentially effective against NAFLD include insulin sensitisers as well as fibrates and omega-3 polyunsaturated fatty acids, while there is reluctance to use statins in patients with suspected or established chronic liver disease. Several other therapeutic options are potentially available, and more data are expected from new peroxisome proliferator-activated receptor agonists and incretin-based therapies.

Original languageEnglish
Pages (from-to)1065-1068
Number of pages4
JournalExpert Opinion on Pharmacotherapy
Volume15
Issue number8
DOIs
Publication statusPublished - 2014

Fingerprint

Fatty Liver
Dyslipidemias
Liver Diseases
Chronic Disease
Incretins
Fibric Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Peroxisome Proliferator-Activated Receptors
Omega-3 Fatty Acids
Therapeutics
Unsaturated Fatty Acids
Life Style
Cardiovascular Diseases
Insulin
Non-alcoholic Fatty Liver Disease
Pharmaceutical Preparations
Population

Keywords

  • cardiovascular risk
  • dyslipidemia
  • non-alcoholic fatty liver disease
  • therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)

Cite this

Treatment options for managing atherogenic dyslipidemia and fatty liver disease. / Rizzo, Manfredi; Montalto, Giuseppe; Al-Rasadi, Khalid.

In: Expert Opinion on Pharmacotherapy, Vol. 15, No. 8, 2014, p. 1065-1068.

Research output: Contribution to journalArticle

@article{6d588e7d99e64258a6a97c92222a5003,
title = "Treatment options for managing atherogenic dyslipidemia and fatty liver disease",
abstract = "Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries with up to 30{\%} of the population affected. Since NAFLD is associated with an increased risk of cardiovascular (CV) disease, these patients should be stratified for CV risk factors, including atherogenic dyslipidemia, and managed accordingly. Lifestyle modifications represent an effective treatment for NAFLD, since most patients are overweight or obese. Also, promising, but not conclusive, results are available for current pharmacologic treatment. Drugs potentially effective against NAFLD include insulin sensitisers as well as fibrates and omega-3 polyunsaturated fatty acids, while there is reluctance to use statins in patients with suspected or established chronic liver disease. Several other therapeutic options are potentially available, and more data are expected from new peroxisome proliferator-activated receptor agonists and incretin-based therapies.",
keywords = "cardiovascular risk, dyslipidemia, non-alcoholic fatty liver disease, therapy",
author = "Manfredi Rizzo and Giuseppe Montalto and Khalid Al-Rasadi",
year = "2014",
doi = "10.1517/14656566.2014.902051",
language = "English",
volume = "15",
pages = "1065--1068",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Treatment options for managing atherogenic dyslipidemia and fatty liver disease

AU - Rizzo, Manfredi

AU - Montalto, Giuseppe

AU - Al-Rasadi, Khalid

PY - 2014

Y1 - 2014

N2 - Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries with up to 30% of the population affected. Since NAFLD is associated with an increased risk of cardiovascular (CV) disease, these patients should be stratified for CV risk factors, including atherogenic dyslipidemia, and managed accordingly. Lifestyle modifications represent an effective treatment for NAFLD, since most patients are overweight or obese. Also, promising, but not conclusive, results are available for current pharmacologic treatment. Drugs potentially effective against NAFLD include insulin sensitisers as well as fibrates and omega-3 polyunsaturated fatty acids, while there is reluctance to use statins in patients with suspected or established chronic liver disease. Several other therapeutic options are potentially available, and more data are expected from new peroxisome proliferator-activated receptor agonists and incretin-based therapies.

AB - Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries with up to 30% of the population affected. Since NAFLD is associated with an increased risk of cardiovascular (CV) disease, these patients should be stratified for CV risk factors, including atherogenic dyslipidemia, and managed accordingly. Lifestyle modifications represent an effective treatment for NAFLD, since most patients are overweight or obese. Also, promising, but not conclusive, results are available for current pharmacologic treatment. Drugs potentially effective against NAFLD include insulin sensitisers as well as fibrates and omega-3 polyunsaturated fatty acids, while there is reluctance to use statins in patients with suspected or established chronic liver disease. Several other therapeutic options are potentially available, and more data are expected from new peroxisome proliferator-activated receptor agonists and incretin-based therapies.

KW - cardiovascular risk

KW - dyslipidemia

KW - non-alcoholic fatty liver disease

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=84900818737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900818737&partnerID=8YFLogxK

U2 - 10.1517/14656566.2014.902051

DO - 10.1517/14656566.2014.902051

M3 - Article

VL - 15

SP - 1065

EP - 1068

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 8

ER -